



**DEPARTMENT OF HEALTH AND HUMAN SERVICES  
PUBLIC HEALTH SERVICE  
FOOD AND DRUG ADMINISTRATION  
CENTER FOR DRUG EVALUATION AND RESEARCH**

---

7520 Standish Place  
Rockville, Maryland 20855  
USA

January 24, 2000

Ref. No. 00-HFD-310I-005

Mens Pharmacy  
Attn: Ms. Kirsty Waugh  
C/o Ink Electronic Media LTD.  
River Road RD 1  
Hamilton, New Zealand

Dear Ms. Waugh:

This is to advise you that the Food and Drug Administration (FDA) has reviewed your web site at the Internet address: <http://www.menspharmacy.COM> and that the drug products VIAGRA® and Propecia® being offered for sale are prescription drugs in the United States (U.S.). FDA is unable to determine that these drug products marketed by your firm have been made in accordance with the U.S. specifications and are the same products marketed legally in the United States. Therefore, the sale and distribution of these products on your Internet web site may be illegal in this country and may be in violation of Title 21 of the United States Code, Sections 331(a), 331(d), and 355(a).

Many prescription drugs available from foreign sources are either products for which there is no U.S. approved counterpart or foreign versions of FDA-approved drugs. In either case, these products are not approved for use in the U.S. and therefore, it is illegal for a foreign source to ship these products into the U.S. In our experience, many drugs obtained from foreign sources that purport to be the same as U.S. approved prescription drugs have been of unknown quality. FDA approves a drug on the basis of scientific data submitted by the drug sponsor to demonstrate that the drug is safe and effective. We cannot provide assurance to the American public that the drugs ordered from your web site are the same products approved by FDA and prescribed by the consumer's physician. In addition, federal law prohibits the sale of prescription drugs to U.S. citizens without a valid prescription, 21 U.S.C. Section 353(b).

The agency is taking steps to warn our citizens that drugs promoted and sold from foreign sources via the Internet may not be approved for marketing in this country. With copies of this letter, we are advising the regulatory drug officials in the countries from which you operate of these potential violations. We are also advising the U.S. Customs Service through an Import Alert that all shipments offered for importation into the United States as a result of your activities may be detained and subject to refusal of entry.

FDA would like to take this opportunity to clarify the agency's policy concerning the importation of pharmaceutical products for personal use. For many years, FDA has permitted individuals and their physicians to bring into the United States small quantities of drugs sold abroad, but not approved in the U.S. for a patient's treatment of a serious condition. This compassionate approach has been applied to products that do not represent an unreasonable risk and for which there is no known commercialization or promotion to persons residing in the U.S. A patient seeking to import such product must also provide the name of the licensed physician in the U.S. responsible for his or her treatment with the unapproved drug product. The Viagra® and Propecia® ordered from your web site do not meet the criteria in FDA's personal use policy.

Please notify this office in writing what you plan to do about these potential violations. Your response may be sent electronically (E-mail) to Mr. William Nychis at the following address: [Nychis@CDER.FDA.GOV](mailto:Nychis@CDER.FDA.GOV). You may also provide written response via fax at (301) 594-0165 or hard copy letter to the letterhead address. Mr. Nychis may be reached by telephone at (301) 594-0063.

Sincerely yours,

/s/

Bradford W. Williams  
Director

Division of Labeling and Non-prescription Drug Compliance